Merck, AstraZeneca Get FDA Priority Review for Selumetinib in NF1

Date : 11/14/2019 @ 12:55PM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7878.0  0.0 (0.00%) @ 12:00AM
Astrazeneca share price Chart

Merck, AstraZeneca Get FDA Priority Review for Selumetinib in NF1

Merck (NYSE:MRK)
Historical Stock Chart

3 Months : From Oct 2019 to Jan 2020

Click Here for more Merck Charts.

By Colin Kellaher


Merck & Co. (MRK) and AstraZeneca PLC (AZN) Thursday said the U.S. Food and Drug Administration accepted and granted priority review to their new-drug application for selumetinib in the rare and incurable genetic condition neurofibromatosis type 1, or NF1.

The drug makers said the NDA covers selumetinib as a potential new medicine for children ages three years and older with NF1 and symptomatic, inoperable plexiform neurofibromas.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period to six months from the standard 10 months. Merck and AstraZeneca said the agency set a target action date for the second quarter of 2020.

AstraZeneca and Merck in 2017 formed a collaboration to develop and commercialize certain oncology products, including selumetinib.


Write to Colin Kellaher at


(END) Dow Jones Newswires

November 14, 2019 07:40 ET (12:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200120 06:55:15